ArticleScience (New York, N.Y.)2014
Antibody landscapes after influenza virus infection or vaccination.
Article in Science (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 335 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
335 citing papers in PubMed, 1 synthesis or guideline pooled it, 507 citations in OpenAlex.
- Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis.The Lancet. Respiratory medicine · 2023Pooled it
- Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.Nature medicine · 2023Trial
- Impaired memory B-cell recall responses in the elderly following recurrent influenza vaccination.PloS one · 2021Trial
- Birth Cohort Effects in Adults Associated With Influenza A(H1N1)pdm09 Vaccine Effectiveness.The Journal of infectious diseases · 2026Article
- Article
- Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants.Nature immunology · 2026Article
- What Antibody Repertoires See: Structural and Immunogenetic Insights Into Influenza A Virus Hemagglutinin Recognition.Immunological reviews · 2026Review
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- The Dual Role of Preexisting Immunity in Influenza: Protective Recall Versus Constraint of Novel Responses.Immunological reviews · 2026Review
- Alignment-free prediction of cross-reactivity in influenza A (H3N2) anticipates antigenic drift.PLoS computational biology · 2026Article
- Repeated influenza vaccination results in blunting rather than back-boosting of antibody responses against A(H3N2) antigens.Research square · 2026Article
- Mechanisms Underlying the Induction of Immunological Imprinting by RNA Viruses and Intervention Strategies.Viruses · 2026Review
- Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults.EBioMedicine · 2026Article
- Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.Journal of virology · 2026Article
- Persistence of memory: lifespan dynamics of the human antiviral antibody reactome.Nature communications · 2026Article
- Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccination.Communications medicine · 2026Article
- Article
- Predicting the antigenic evolution of seasonal influenza viruses using phylogenetic convergence.bioRxiv : the preprint server for biology · 2026Article
- Bang-bang control optimization in infectious disease model with incorporating breakthrough and reinfection.Scientific reports · 2026Article
- Understanding patterns of variant emergence and spread in an ongoing epidemic.medRxiv : the preprint server for health sciences · 2026Article
275 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 5 institutions in 3 countries.
Funding
Abstract
We introduce the antibody landscape, a method for the quantitative analysis of antibody-mediated immunity to antigenically variable pathogens, achieved by accounting for antigenic variation among pathogen strains. We generated antibody landscapes to study immune profiles covering 43 years of influenza A/H3N2 virus evolution for 69 individuals monitored for infection over 6 years and for 225 individuals pre- and postvaccination. Upon infection and vaccination, titers increased broadly, including previously encountered viruses far beyond the extent of cross-reactivity observed after a primary infection. We explored implications for vaccination and found that the use of an antigenically advanced virus had the dual benefit of inducing antibodies against both advanced and previous antigenic clusters. These results indicate that preemptive vaccine updates may improve influenza vaccine efficacy in previously exposed individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.